vs

Side-by-side financial comparison of Brookfield Asset Management Ltd. (BAM) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Brookfield Asset Management Ltd. is the larger business by last-quarter revenue ($1.1B vs $961.0M, roughly 1.1× DENTSPLY SIRONA Inc.). Brookfield Asset Management Ltd. runs the higher net margin — 56.7% vs -15.2%, a 71.9% gap on every dollar of revenue.

Brookfield Asset Management Ltd. is a Canadian-American alternative asset manager. The company was founded in December 2022 as a spin-off of the asset management operations of Brookfield Corporation, and manages investments across real estate, infrastructure, renewable energy, private equity, and credit markets globally.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

BAM vs XRAY — Head-to-Head

Bigger by revenue
BAM
BAM
1.1× larger
BAM
$1.1B
$961.0M
XRAY
Higher net margin
BAM
BAM
71.9% more per $
BAM
56.7%
-15.2%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BAM
BAM
XRAY
XRAY
Revenue
$1.1B
$961.0M
Net Profit
$615.0M
$-146.0M
Gross Margin
46.1%
Operating Margin
84.2%
-14.5%
Net Margin
56.7%
-15.2%
Revenue YoY
6.2%
Net Profit YoY
66.0%
EPS (diluted)
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAM
BAM
XRAY
XRAY
Q4 25
$1.1B
$961.0M
Q3 25
$974.0M
$904.0M
Q2 25
$931.0M
$936.0M
Q1 25
$954.0M
$879.0M
Q4 24
$905.0M
Q3 24
$873.0M
$951.0M
Q2 24
$821.0M
$984.0M
Q1 24
$786.0M
$953.0M
Net Profit
BAM
BAM
XRAY
XRAY
Q4 25
$615.0M
$-146.0M
Q3 25
$692.0M
$-427.0M
Q2 25
$584.0M
$-45.0M
Q1 25
$507.0M
$20.0M
Q4 24
$-430.0M
Q3 24
$537.0M
$-494.0M
Q2 24
$124.0M
$-4.0M
Q1 24
$373.0M
$18.0M
Gross Margin
BAM
BAM
XRAY
XRAY
Q4 25
46.1%
Q3 25
48.8%
Q2 25
52.4%
Q1 25
53.0%
Q4 24
49.3%
Q3 24
52.1%
Q2 24
51.9%
Q1 24
53.1%
Operating Margin
BAM
BAM
XRAY
XRAY
Q4 25
84.2%
-14.5%
Q3 25
79.1%
-24.1%
Q2 25
70.8%
-13.7%
Q1 25
61.0%
7.2%
Q4 24
-56.2%
Q3 24
72.5%
-48.6%
Q2 24
80.4%
5.1%
Q1 24
56.5%
4.4%
Net Margin
BAM
BAM
XRAY
XRAY
Q4 25
56.7%
-15.2%
Q3 25
71.0%
-47.2%
Q2 25
62.7%
-4.8%
Q1 25
53.1%
2.3%
Q4 24
-47.5%
Q3 24
61.5%
-51.9%
Q2 24
15.1%
-0.4%
Q1 24
47.5%
1.9%
EPS (diluted)
BAM
BAM
XRAY
XRAY
Q4 25
$-0.74
Q3 25
$-2.14
Q2 25
$-0.22
Q1 25
$0.10
Q4 24
$-2.09
Q3 24
$-2.46
Q2 24
$-0.02
Q1 24
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAM
BAM
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$1.6B
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$8.9B
$1.3B
Total Assets
$17.0B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAM
BAM
XRAY
XRAY
Q4 25
$1.6B
$326.0M
Q3 25
$1.1B
$363.0M
Q2 25
$480.0M
$359.0M
Q1 25
$332.0M
$398.0M
Q4 24
$272.0M
Q3 24
$296.0M
Q2 24
$10.0M
$279.0M
Q1 24
$291.0M
Total Debt
BAM
BAM
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BAM
BAM
XRAY
XRAY
Q4 25
$8.9B
$1.3B
Q3 25
$8.5B
$1.5B
Q2 25
$8.5B
$2.0B
Q1 25
$8.5B
$2.0B
Q4 24
$1.9B
Q3 24
$9.0B
$2.5B
Q2 24
$3.2B
$3.1B
Q1 24
$2.2B
$3.3B
Total Assets
BAM
BAM
XRAY
XRAY
Q4 25
$17.0B
$5.4B
Q3 25
$16.5B
$5.7B
Q2 25
$16.1B
$6.1B
Q1 25
$15.0B
$6.0B
Q4 24
$5.8B
Q3 24
$6.6B
Q2 24
$4.2B
$6.9B
Q1 24
$7.1B
Debt / Equity
BAM
BAM
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAM
BAM
XRAY
XRAY
Operating Cash FlowLast quarter
$562.0M
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAM
BAM
XRAY
XRAY
Q4 25
$562.0M
$101.0M
Q3 25
$745.0M
$79.0M
Q2 25
$529.0M
$48.0M
Q1 25
$265.0M
$7.0M
Q4 24
$87.0M
Q3 24
$567.0M
$141.0M
Q2 24
$159.0M
$208.0M
Q1 24
$516.0M
$25.0M
Free Cash Flow
BAM
BAM
XRAY
XRAY
Q4 25
$60.0M
Q3 25
$40.0M
Q2 25
$16.0M
Q1 25
$-12.0M
Q4 24
$36.0M
Q3 24
$98.0M
Q2 24
$156.0M
Q1 24
$-9.0M
FCF Margin
BAM
BAM
XRAY
XRAY
Q4 25
6.2%
Q3 25
4.4%
Q2 25
1.7%
Q1 25
-1.4%
Q4 24
4.0%
Q3 24
10.3%
Q2 24
15.9%
Q1 24
-0.9%
Capex Intensity
BAM
BAM
XRAY
XRAY
Q4 25
4.3%
Q3 25
4.3%
Q2 25
3.4%
Q1 25
2.2%
Q4 24
5.6%
Q3 24
4.5%
Q2 24
5.3%
Q1 24
3.6%
Cash Conversion
BAM
BAM
XRAY
XRAY
Q4 25
0.91×
Q3 25
1.08×
Q2 25
0.91×
Q1 25
0.52×
0.35×
Q4 24
Q3 24
1.06×
Q2 24
1.28×
Q1 24
1.38×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAM
BAM

Incentive Fees$452.0M42%
Infrastruture$332.0M31%
Private Equity$174.0M16%
Renewable Power And Transition$66.0M6%
Other$47.0M4%
Management And Advisory Fees$14.0M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons